Antibiotics Removal by Continuous Venovenous Hemofiltration with a Novel Asymmetric Triacetate Membrane Hemofilter: An in vitro Study

被引:6
作者
Kortge, Andreas [1 ,2 ]
Majcher-Peszynska, Jolanta [3 ]
Heskamp, Benjamin [1 ,2 ]
Wasserkort, Reinhold [1 ,2 ]
Mitzner, Steffen [1 ,2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Dept Extracorporeal Immunomodulat EXIM, Schillingallee 68,Room 1-06, DE-18057 Rostock, Germany
[2] Univ Med Rostock, Ctr Internal Med, Div Nephrol, Rostock, Germany
[3] Univ Med Rostock, Inst Pharmacol & Toxicol, Rostock, Germany
关键词
Continuous renal replacement therapy; Hemofiltration; Acute kidney injury; Sepsis; Antibiotics removal;
D O I
10.1159/000513417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Continuous renal replacement therapies (CRRTs) are essential in the treatment of critically ill patients with acute kidney injury and are also discussed as a supporting sepsis therapy. CRRT can affect antibiotics plasma concentrations. Objective: The effect of continuous venovenous hemofiltration (CVVH) with an asymmetric triacetate (ATA) membrane hemofilter on concentrations of antibiotics with low (meropenem), medium (vancomycin), and high (daptomycin) protein binding (PB) was investigated. Methods: 1 L human whole blood supplemented with antibiotics was recirculated and filtrated for 6 h in vitro. Clearances and sieving coefficients (SC) were determined from antibiotics concentrations measured at filter inlet, outlet, and filtrate side. Reservoir concentration data were fitted using a first-order kinetic model. Results: Meropenem and vancomycin concentrations decreased to 5-10% of the initial plasma level, while only 50% of daptomycin were removed. Clearances and SCs were (10.8 [10.8-17.4] mL/min, SC = 0.72 [0.72-1.16]) for meropenem, (13.4 [12.3-13.7] mL/min, 0.89 [0.82-0.92]) for vancomycin, and (2.1 [1.8-2.1] mL/min, 0.14 [0.12-0.14]) for daptomycin. Removal by adsorption was negligible. Conclusions: The clearances and SCs presented are comparable with findings of other authors. Meropenem and vancomycin, which exhibit low and medium PB, respectively, were strongly removed, while considerably less daptomycin was removed because of its high PB. Our results suggest that in clinical use of the tested antibiotics during CRRT with the ATA hemofilter, the same factors have to be considered for determining the dosing strategy as with filters with other commonly applied membrane materials.
引用
收藏
页码:899 / 905
页数:7
相关论文
共 35 条
  • [1] Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
    Abdul-Aziz, Mohd H.
    Alffenaar, Jan-Willem C.
    Bassetti, Matteo
    Bracht, Hendrik
    Dimopoulos, George
    Marriott, Deborah
    Neely, Michael N.
    Paiva, Jose-Artur
    Pea, Federico
    Sjovall, Fredrik
    Timsit, Jean F.
    Udy, Andrew A.
    Wicha, Sebastian G.
    Zeitlinger, Markus
    De Waele, Jan J.
    Roberts, Jason A.
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (06) : 1127 - 1153
  • [2] Mediators of Inflammation in Acute Kidney Injury
    Akcay, Ali
    Nguyen, Quocan
    Edelstein, Charles L.
    [J]. MEDIATORS OF INFLAMMATION, 2009, 2009
  • [3] Optimizing the Clinical Use of Vancomycin
    Alvarez, Rocio
    Lopez Cortes, Luis E.
    Molina, Jose
    Cisneros, Jose M.
    Pachon, Jeronimo
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2601 - 2609
  • [4] Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration
    Bilgrami, I.
    Roberts, J. A.
    Wallis, S. C.
    Thomas, J.
    Davis, J.
    Fowler, S.
    Goldrick, P. B.
    Lipman, J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2974 - 2978
  • [5] Bodmann K.-F., 2019, Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen-Update 2018: PEG S2k Leitlinie (AWMF-Registernummer 082-006)
  • [6] Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients
    Boereboom, FTJ
    Ververs, FFT
    Blankestijn, PJ
    Savelkoul, TJF
    van Dijk, A
    [J]. INTENSIVE CARE MEDICINE, 1999, 25 (10) : 1100 - 1104
  • [7] Daptomycin clearance during modeled continuous renal replacement therapy
    Churchwell, Mariann D.
    Pasko, Deborah A.
    Mueller, Bruce A.
    [J]. BLOOD PURIFICATION, 2006, 24 (5-6) : 548 - 554
  • [8] A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: Application to a clinical pharmacokinetic study
    Dailly, E.
    Bouquie, R.
    Deslandes, G.
    Jolliet, P.
    Le Floch, R.
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (15-16): : 1137 - 1142
  • [9] De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846
  • [10] Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
    Dvorchik, BH
    Brazier, D
    DeBruin, MF
    Arbeit, RD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1318 - 1323